Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Wren Therapeutics logo — Stopping the wave of neurodegeneration at its source

Wren Therapeutics

Stopping the wave of neurodegeneration at its source

Founded 2016 United Kingdom Cambridge, United Kingdom 34 employees Venture round Total: $30.40M Biopharma, Biotechnology +2

General Information

Company Name Wren Therapeutics
Founded Year 2016
Location United Kingdom Cambridge, United Kingdom
Employees 34
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Wren Therapeutics. To contact Wren Therapeutics, visit wrentherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Wren Therapeutics compare?

A PDF of Wren Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Wren Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Wren Therapeutics

Wren Therapeutics is a biopharmaceutical company that has transformed drug discovery for neurodegenerative diseases through its platform, WaveBreak. This platform targets protein intermediates central to disease pathways, specifically focusing on the oligomers that are beyond the reach of conventional drug discovery approaches. By interrupting the molecular mechanisms generating oligomers with small-molecule therapeutics, WaveBreak aims to address some of the greatest unmet medical needs of our time, including Parkinson’s disease, Alzheimer’s disease, and ALS. Established in 2016, the United Kingdom-based company has attracted notable attention, receiving a recent £12.40M Venture Round investment on 25 January 2021 from investors such as Industry Ventures, Schooner Capital, LifeForce Capital, and The Baupost Group. With a focus on biopharma, biotechnology, healthcare, and pharmaceutical industries, WaveBreak's innovative approach and targeted focus areas position it as a compelling prospect for potential investors seeking to make an impact in the neurodegenerative disease treatment space.

Business keywords: neurodegenerative diseases, biopharmaceutical company, drug discovery, protein misfolding diseases, small-molecule therapeutics, Parkinson's disease, Alzheimer's disease, ALS, Wren Therapeutics, Cambridge UK, new technology platform, protein intermediates, oligomers, rare disorders, University of Cambridge

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round £12.40M 4
Industry Ventures Schooner Capital LifeForce Capital
Industry Ventures, Schooner Capital +2
25 Jan 2021
Series A £18.00M 2
LifeForce Capital
LifeForce Capital, The Baupost Group
22 Jan 2019
Venture Round Undisclosed 1
Malin Corporation
16 Jan 2017

Wren Therapeutics Alternatives & Competitors

View All Alternatives
Wren Therapeutics vs
Asceneuron SA
Asceneuron SA Switzerland

Targeting the root cause of neurodegeneration

Series C
20 employees
Biotechnology, Health Care
Compare Wren Therapeutics vs Asceneuron SA
Wren Therapeutics vs
Kineta (Reverse Merger With Yumanity Therapeutics)
Kineta (Reverse Merger With Yumanity Therapeutics)

Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfolding.

Venture round
Biotechnology, Health Care
Compare Wren Therapeutics vs Kineta (Reverse Merger With Yumanity Therapeutics)
Wren Therapeutics vs
Gain Therapeutics
Gain Therapeutics United States

Unfolding the next generation of allosteric small molecule therapies to meet patient needs

IPO
26 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Wren Therapeutics

Stopping the wave of neurodegeneration at its source
Wren Therapeutics was founded in 2016.
Wren Therapeutics is headquartered in Cambridge, United Kingdom.
Wren Therapeutics operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on neurodegenerative diseases, biopharmaceutical company, drug discovery and protein misfolding diseases.
Wren Therapeutics has approximately 34 employees.
Wren Therapeutics has completed 3 funding rounds, raising a total of $30.40M. The latest funding stage is Venture round.
Top alternatives and competitors to Wren Therapeutics include Asceneuron SA, Kineta (Reverse Merger With Yumanity Therapeutics), Gain Therapeutics, Hinge Therapeutics, Navitor Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Wren Therapeutics and Asceneuron SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Wren Therapeutics, https://bouncewatch.com/company/wren-therapeutics, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout